ALQA's Subsidiary Enters Cannabis Space, TYME On Watch, VXRT Turning Heads

pharmaup nov28

The following are some of today's top gainers in the pharma/biotech sector.

1. Alliqua BioMedical Inc. (ALQA)

Gained 63.19% to close Wednesday's (Nov.28) trading at $2.66.

News: The Company is all set to spin off its AquaMed Technologies Inc. subsidiary and merge it with TO Pharmaceuticals LLC to create an independent, publicly traded company focused on cannabinoid-based pharmaceutical therapies.

The transaction has been approved by the boards of both Alliqua and TOP, and is expected to close by the first quarter of 2019.

2. ACADIA Pharmaceuticals Inc. (ACAD)

Gained 20.76% to close Wednesday's trading at $20.53.

News: The Company has priced an underwritten public offering of 16.18 million shares of its common stock at $17.00 per share.

The gross proceeds from this offering to ACADIA are expected to be approximately $275.0 million. The underwriters have a 30-day option to purchase up to an aggregate of 2.43 million additional shares of common stock.

The offering is expected to close on November 30, 2018, subject to customary closing conditions.

3. Vaxart Inc. (VXRT)

Gained 25.49% to close Wednesday's trading at $3.20.

News: The Company presented summary data from its phase II Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California.

On October 4, the Company announced that its oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Sanofi's Fluzone in the phase II challenge study.

4. Tyme Technologies Inc. (TYME)

Gained 18.08% to close Wednesday's trading at $3.20.


The lead product candidate is SM-88, which is currently being evaluated in two ongoing Phase II clinical trials for metastatic pancreatic cancer and prostate cancer.

Near-term Catalysts:

-- Interim data from Stage 1 of the phase II trial of SM-88 in pancreatic cancer is expected to be presented on January 18, 2019.
-- Updated data from the phase II trial of SM-88 in prostate cancer is expected in the first quarter of calendar year 2019.

5. Forty Seven Inc. (FTSV)

Forty Seven is a clinical-stage immuno-oncology company.

Gained 13.39% to close Wednesday's trading at $18.38.

News: No news


The most advanced ongoing clinical trial is a phase 1b/2 combination trial using 5F9 and rituximab in patients with relapsed and refractory NHL. A phase 1b/2 combination clinical trial of 5F9 and cetuximab in patients with advanced relapsed or refractory solid tumors, including colorectal cancer is also underway.

FSI-189, an anti-SIRPa antibody, for the treatment of cancer is under preclinical testing.

Recent event:

The Company went public on the Nasdaq Global Select Market on June 28, 2018, offering its shares at a price of $16 each.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT